Literature DB >> 27487199

Targeting CYP51 for drug design by the contributions of molecular modeling.

Vitor W Rabelo1, Taísa F Santos1, Luciana Terra2, Marcos V Santana2, Helena C Castro2, Carlos R Rodrigues3, Paula A Abreu1.   

Abstract

CYP51 is an enzyme of sterol biosynthesis pathway present in animals, plants, protozoa and fungi. This enzyme is described as an important drug target that is still of interest. Therefore, in this work, we reviewed the structure and function of CYP51 and explored the molecular modeling approaches for the development of new antifungal and antiprotozoans that target this enzyme. Crystallographic structures of CYP51 of some organisms have already been described in the literature, which enable the construction of homology models of other organisms' enzymes and molecular docking studies of new ligands. The binding mode and interactions of some new series of azoles with antifungal or antiprotozoan activities has been studied and showed important residues of the active site. Molecular modeling is an important tool to be explored for the discovery and optimization of CYP51 inhibitors with better activities, pharmacokinetics, and toxicological profiles.
© 2016 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  CYP51; antifungal; antiprotozoan; drug design; molecular modeling

Mesh:

Substances:

Year:  2016        PMID: 27487199     DOI: 10.1111/fcp.12230

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  5 in total

1.  Synthesis, Molecular Docking, and Antimycotic Evaluation of Some 3-Acyl Imidazo[1,2-a]pyrimidines.

Authors:  Omar Gómez-García; Dulce Andrade-Pavón; Elena Campos-Aldrete; Ricardo Ballinas-Indilí; Alfonso Méndez-Tenorio; Lourdes Villa-Tanaca; Cecilio Álvarez-Toledano
Journal:  Molecules       Date:  2018-03-07       Impact factor: 4.411

Review 2.  Roles for Structural Biology in the Discovery of Drugs and Agrochemicals Targeting Sterol 14α-Demethylases.

Authors:  Brian C Monk; Mikhail V Keniya
Journal:  J Fungi (Basel)       Date:  2021-01-20

3.  Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment.

Authors:  Junmei Shang; Shurong Ma; Caixia Zang; Xiuqi Bao; Yan Wang; Dan Zhang
Journal:  Acta Pharm Sin B       Date:  2021-01-26       Impact factor: 11.413

4.  Prediction of Drug-Target Interaction Networks from the Integration of Protein Sequences and Drug Chemical Structures.

Authors:  Fan-Rong Meng; Zhu-Hong You; Xing Chen; Yong Zhou; Ji-Yong An
Journal:  Molecules       Date:  2017-07-05       Impact factor: 4.411

5.  Synthesis, Optimization, Antifungal Activity, Selectivity, and CYP51 Binding of New 2-Aryl-3-azolyl-1-indolyl-propan-2-ols.

Authors:  Nicolas Lebouvier; Fabrice Pagniez; Young Min Na; Da Shi; Patricia Pinson; Mathieu Marchivie; Jean Guillon; Tarek Hakki; Rita Bernhardt; Sook Wah Yee; Claire Simons; Marie-Pierre Lézé; Rolf W Hartmann; Angélique Mularoni; Guillaume Le Baut; Isabelle Krimm; Ruben Abagyan; Patrice Le Pape; Marc Le Borgne
Journal:  Pharmaceuticals (Basel)       Date:  2020-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.